



Elekta declines to continue to participate in linear accelerator bidding process in Brazil

Stockholm, October 22, 2013 – Elekta has declined to continue to participate in a linear accelerator bidding process at the Ministry of Health in Brazil. During a reverse auction, the price for 80 linear accelerators, a customer service and support package, as well as project management, comprehensive software solutions and brachytherapy equipment, went below BRL 120 million (USD 55 million) which includes 5% tax – a point that Elekta could not commit to.

“We decided we had to decline participation in this tender when the price went to unsustainable levels. This is a program where we believe Brazil will require modern digital linear accelerator systems. The tender includes long-term service commitments, as well as training and additional machines. Elekta does not consider it possible to deliver the right quality and support to our Brazilian customer base at that price level,” says Elekta President and CEO, Tomas Puusepp.

Puusepp added: “Brazil continues to be a growth market for us, with many patients that will need access to modern radiation therapy in this decade. Despite our decision to decline participation in this particular tender, Elekta will continue to invest in the development and modernization of Brazilian cancer care.”

###

For further information, please contact:

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 12:00 CET on October 22, 2013.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO: EKTAB. Website: www.elekta.com.